You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: Flow Pharma, Inc. Topic: CBD18A002
Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
SBC: NANOSD, INC. Topic: DEFOA0001429
NanoSD, Inc. with its partners will develop a transparent, nanostructured thermally insulating film that can be applied to existing single-pane windows to reduce heat loss. To produce the nanostructured film, the team will create hollow ceramic or polymer nanobubbles and consolidate them into a dense lattice structure using heat and compression. Because it is mostly air, the resulting nanobubble s ...STTR Phase II 2016 Department of EnergyARPA-E
SBC: PATHOVACS INCORPORATED Topic: CBD18A001
The focus of this STTR phase I component is on proof-of-concept studies demonstrating applicability of technical approaches for identificationof circulatory diagnostic markers for infectious disease. Therefore, the primary objective of this project is to determine feasibility of one suchtechnical approach called Proteomics-based Expression Library Screening (PELS), for identification of pathogen-d ...STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
SBC: MAPP BIOPHARMACEUTICAL, INC. Topic: CBD18A002
There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
SBC: Luna Innovations Incorporated Topic: CBD18A002
Marburg virus (MARV) is a filamentous enveloped non-segmented negative sense RNA virus. This viruse is considered to be extremelydangerous with case fatality rates as high as 88-90%. Extensive efforts have gone towards effective vaccines for MARV prevention, however,none have been successfully established as licensed vaccines. Glycoprotein (GP) is the only surface protein of MARV. There are substa ...STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
SBC: RELIABLE MICROSYSTEMS LLC Topic: DTRA16A003
Establish a radiation-aware analysis capability in a commercial EDA design flow that will enable first-pass success in radiation-hardened by design (RHBD) for DoD ASICs in much the same way that existing EDA design suites ensure first pass functionality and performance success of complex ASICs destined for commercial applications. Layout-aware, calibrated single-event radiation models that captur ...STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency
Hierarchical, Layout-Aware, Radiation Effects Tools Vertically Integrated into an EDA Design Flow for Rad-Hard by DesignSBC: RELIABLE MICROSYSTEMS LLC Topic: DTRA16A003
The goal of this workis to establish a radiation-aware capability in a commercial EDA design flow that will enable first-pass success in radiation resiliency for DoD ASIC designs in much the same way that existing EDA design suites ensure first pass functionality and performance success of complex ASICs destined for commercial applications.Such an integrated capability does not presently exist.The ...STTR Phase II 2018 Department of DefenseDefense Threat Reduction Agency
SBC: MATSYS INC Topic: DTRA16A001
MATSYS proposes to adapt emerging additive manufacturing techniques (so-called 3-D Printing) for use with reactive structural materials and demonstrate this capability to rapidly fabricate reactive case. Our concept incorporates two major manufacturing steps: 3D printing of green compacts from pure Al or Al-based reactive powder blend; and Microwave (MW) sintering of green compacts into net-shaped ...STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency
SBC: MATSYS INC Topic: DTRA16A002
MATSYS proposes to develop, test and evaluate a scalable metal-based reactive structural material that will self-fragment to micron or sub-micron scale fuel particles when subjected to explosive shock loading, resulting in significantly enhanced metal combustion efficiency. Use of reactive material casings offers the potential for several-fold increases in blast and overpressure by generating rapi ...STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency
SBC: SCIENTIFIC APPLICATIONS & RESEARCH ASSOCIATES, INC. Topic: DTRA16A004
For effective protection against EMP and HPM threats, it is important to understand the physics of the threats, and also to quantify the effects they have on electrical systems. EMP and HPM vulnerability testing requires delivery of high peak power and electric fields to distant targets. The most practical solution to simulate such environments is to develop a modular, optically-isolated MV-antenn ...STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency